Helen Louise Collins, CHIEF MEDICAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 5,000 shares at $39.53 ($199K) on 2026-05-18, disclosed to the SEC on 2026-05-20.
Scheduled sale ($199k) by CHIEF MEDICAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.53 | 3,475 | $137K | 69.0% |
| 2 | $40.25 | 1,302 | $52K | 26.3% |
| 3 | $41.21 | 223 | $9K | 4.6% |
| Total | $39.79 avg | 5,000 | $199K | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $263K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $219K | — | Filing → |
| ELVN | SELL | 2026-04-21 | $238K | — | Filing → |